Participants in HIV clinical trials in Europe

被引:4
|
作者
Schrooten, W [1 ]
Borchert, M [1 ]
Dreezen, C [1 ]
Baratta, C [1 ]
Smets, E [1 ]
Kosmidis, J [1 ]
Goebel, FD [1 ]
Wilkins, EG [1 ]
Colebunders, R [1 ]
机构
[1] Inst Trop Med, B-2000 Antwerp, Belgium
关键词
HIV infection; clinical trials; Europe;
D O I
10.1258/0956462011916857
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
In recent years an increasing number of antiretrovirals have become available. In order to define the optimal treatment regimens an increasing number of clinical trials are needed. Our objective was to study the profile of participants in HIV clinical trials in Europe and learn from their experience and views. Between August 1996 and September 1997, self-administered anonymous questionnaires were distributed to people with HIV infection at inpatient and outpatient clinics in 11 European countries. One thousand three hundred and sixty-six people completed the questionnaire (50% response rate). Four hundred and twenty (31%) of the respondents reported that they had previously participated in at least one HIV clinical trial. The percentage of people who had taken part in a clinical trial varied widely between the different centres, from 12% in Athens to 61% in Antwerp and Brussels. A significantly higher participation rate was observed in the northern and central part of Europe compared with the south (respectively 40% vs 18%) and also among people with a higher income. Most people (92%) stated that they were 'well' or 'very well' informed prior to enrolment in the trial. However, 4% reported that they had not given written approval and 22% felt that they were pushed into participating. Only 21% stated that they were informed about the outcome of the study on its completion. The most important reason for non-participation (37% of the non-participants) was because a clinical trial had never been proposed. In conclusion, a majority of people with HIV infection in European HIV treatment reference centres were willing to participate in clinical trials. HIV clinical trials in Europe should adhere more strictly to universal ethical standards.
引用
收藏
页码:94 / 99
页数:6
相关论文
共 50 条
  • [1] Selecting participants for clinical trials
    Keech, AC
    Gebski, VJ
    MEDICAL JOURNAL OF AUSTRALIA, 2001, 175 (09) : 490 - +
  • [2] Safeguarding participants in clinical trials
    不详
    LANCET, 2000, 355 (9222): : 2177 - 2177
  • [3] Help wanted: Participants for clinical trials
    Mitka, M
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (12): : 1567 - 1568
  • [5] RETAINING TRIAL PARTICIPANTS Some participants depend on clinical trials
    Selley, Peter
    BMJ-BRITISH MEDICAL JOURNAL, 2022, 376
  • [6] Evaluation of Broadly Neutralizing Antibody Sensitivity by Genotyping and Phenotyping for Qualifying Participants to HIV Clinical Trials
    Moldt, Brian
    Parvangada, Aiyappa
    Martin, Ross
    Pace, Craig
    Balakrishnan, Mini
    Thomsen, Nathan D.
    Collins, Sean E.
    Kuster, Herbert
    Braun, Dominique L.
    Gunthard, Huldrych F.
    Geleziunas, Romas
    Callebaut, Christian
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2021, 88 (01) : 61 - 69
  • [7] SARS-CoV-2 Booster Vaccination for Participants in "HIV Cure"-Related Clinical Trials
    Peluso, Michael J.
    Williams, Meghann C.
    Campbell, Danielle M.
    Dee, Lynda
    Taylor, Jeff
    Ngo, Lynn H.
    Hoh, Rebecca
    Dube, Karine
    Sauceda, John A.
    Deeks, Steven G.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2022, 89 (03) : E33 - +
  • [8] Participants' perspectives on safety monitoring in clinical trials
    Flynn, Kathryn E.
    Kramer, Judith M.
    Dombeck, Carrie B.
    Weinfurt, Kevin P.
    CLINICAL TRIALS, 2013, 10 (04) : 552 - 559
  • [9] The rights and interests of participants as limits to clinical trials
    Dal-Re, R.
    REVISTA CLINICA ESPANOLA, 2025, 225 (01): : 28 - 34
  • [10] Regulating clinical trials in Europe
    Willmott, Glenis
    LANCET ONCOLOGY, 2013, 14 (06): : 453 - +